Walleye Capital’s Fortress Biotech FBIO Stock Holding History

Walleye Capital’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,000	Closed	-$40K	–	881
2020 Q2	$40K	Buy	+1,000	New	+$37.1K	0.01%	553

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Walleye Capital's FBIO Position: Q3 2020 in Review

Walleye Capital sold out of Fortress Biotech (FBIO) in Q3 2020, closing a stake of 1,000 shares — an estimated $40K sold.

Walleye Capital first reported a position in FBIO in Q2 2020 and held it in 1 quarter. The position peaked at $40K in Q2 2020. 77 funds tracked by Wall St. Rank hold FBIO as of Q3 2020.

Walleye Capital reported no remaining Fortress Biotech position as of Q3 2020 after selling out during the quarter.
Walleye Capital sold 1,000 Fortress Biotech shares in Q3 2020, an estimated $40K.
Walleye Capital first reported a position in Fortress Biotech in Q2 2020 and held it in 1 quarter.
Walleye Capital's Fortress Biotech position peaked at $40K in Q2 2020.
77 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2020.

Based on Walleye Capital's 13F filing for Q3 2020, filed 16 Nov 2020.